Blocking LPA signaling through LPAR1 in vivo produces major changes to ENS architecture, abnormal gastrointestinal motility, and, in some cases, a failure of gut motility that is reminiscent of CIPO in humans. This evidence concerns the gene LPAR1 and chronic intestinal pseudoobstruction.